PMAT与OCT1基因变异及合用转运体抑制药与二甲双胍胃肠道不耐受的关联:IMI DIRECT研究
研究纳入286例严重二甲双胍不耐受和1128例耐受的2型糖尿病患者,分析SLC29A4和SLC22A1基因变异及合用药物与不耐受的关联。结果发现女性、高龄、合用转运体抑制药及SLC29A4 rs3889348 G等位基因与不耐受风险升高相关,基因风险评分高者风险加倍。
要点
- 女性和高龄者二甲双胍胃肠道不耐受风险更高。
- 合用转运体抑制药增加不耐受风险(OR 1.72)。
- SLC29A4 rs3889348 G等位基因与不耐受相关(OR 1.34)。
核心结论
- 肠道二甲双胍转运体和合并用药在二甲双胍胃肠道不良反应中起重要作用。
研究设计与样本
- 病例对照研究,纳入IMI DIRECT联盟中286例严重二甲双胍不耐受和1128例耐受的2型糖尿病患者。
主要发现
- 女性(P < 0.001)和年龄较大者(P < 0.001)更易发生二甲双胍不耐受。
- 合用转运体抑制药增加不耐受风险(OR 1.72,P < 0.001)。
- 校正模型中,SLC29A4 rs3889348 G等位基因与胃肠道不耐受相关(OR 1.34,P = 0.005)。
- rs3889348是肠道组织中SLC29A4的主要顺式表达数量性状位点,G等位基因携带者表达降低。
- 携带G等位基因且合用转运体抑制药者不耐受风险较无G等位基因且未用药者高3倍以上(OR 3.23,P < 0.001)。
临床怎么用
- 对二甲双胍不耐受患者,可关注性别、年龄、合并使用转运体抑制药及SLC29A4/SLC22A1基因变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastrointestinal adverse effects occur in 20-30% of patients with metformin-treated type 2 diabetes, leading to premature discontinuation in 5-10% of the cases. Gastrointestinal intolerance may reflect localized high concentrations of metformin in the gut. We hypothesized that reduced transport of metformin via the plasma membrane monoamine transporter (PMAT) and organic cation transporter 1 (OCT1) could increase the risk of severe gastrointestinal adverse effects. RESEARCH DESIGN AND METHODS: The study included 286 severe metformin-intolerant and 1,128 metformin-tolerant individuals from the IMI DIRECT (Innovative Medicines Initiative: DIabetes REsearCh on patient straTification) consortium. We assessed the association of patient characteristics, concomitant medication, and the burden of mutations in the SLC29A4 and SLC22A1 genes on odds of intolerance. RESULTS: Women (P < 0.001) and older people (P < 0.001) were more likely to develop metformin intolerance. Concomitant use of transporter-inhibiting drugs increased the odds of intolerance (odds ratio [OR] 1.72, P < 0.001). In an adjusted logistic regression model, the G allele at rs3889348 (SLC29A4) was associated with gastrointestinal intolerance (OR 1.34, P = 0.005). rs3889348 is the top cis-expression quantitative trait locus for SLC29A4 in gut tissue where carriers of the G allele had reduced expression. Homozygous carriers of the G allele treated with transporter-inhibiting drugs had more than three times higher odds of intolerance compared with carriers of no G allele and not treated with inhibiting drugs (OR 3.23, P < 0.001). Use of a genetic risk score derived from rs3889348 and SLC22A1 variants found that the odds of intolerance were more than twice as high in individuals who carry three or more risk alleles compared with those carrying none (OR 2.15, P = 0.01). CONCLUSIONS: These results suggest that intestinal metformin transporters and concomitant medications play an important role in the gastrointestinal adverse effects of metformin.
引用
- Dawed AY, Zhou K, van Leeuwen N, et al. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care. 2019. PMID: 30885951. doi:10.2337/dc18-2182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。